Creative Medical Technology Holdings, Inc. (CELZ)
| Market Cap | 6.75M-75.1% |
| Revenue (ttm) | 3.00K |
| Net Income | -6.04M |
| EPS | -2.07 |
| Shares Out | 7.59M |
| PE Ratio | n/a |
| Forward PE | -1.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,382 |
| Open | 0.88 |
| Previous Close | 0.88 |
| Day's Range | 0.88 - 0.89 |
| 52-Week Range | 0.62 - 6.25 |
| Beta | 1.91 |
| Analysts | none |
| Price Target | 20.00(+2149.72%) |
| Earnings Date | n/a |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CELZ
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CELZ stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CELZ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CELZ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CELZ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CELZ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CELZ from public contracts
Source: USAspending.gov
CELZ Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CELZ’s recent data — informational, not investment advice